Payment overview · 2025
General Payments
$486.00
18 reported records · 6 companies
Healthcare provider profile · identity verified
William Richard Ford, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · RENO, NV · NPI 1356916597
Verified facts
What the public records show
CMS Open Payments records show William Richard Ford, APRN received $486.00 in general payments during 2025 across 18 reported records.
Lundbeck LLC accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $177.10 | 36.4% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $160.87 | 33.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $77.76 | 16.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.33 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.72 | 5.3% | 1 | 2025 |
| Movair Inc | Unresolved — no canonical attribution shown | $16.22 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $486.00 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $177.10 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $77.76 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.97 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| LUISA Normalized: luisa |
Device | Movair Inc | $16.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 502 | 174 |
| Losartan Potassium | Losartan Potassium | 444 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 398 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 112 |
| Lisinopril | Lisinopril | 335 | 109 |
| Omeprazole | Omeprazole | 228 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 69 |
| Trazodone Hcl | Trazodone Hcl | 201 | 68 |
| Gabapentin | Gabapentin | 200 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 45 |
| Myrbetriq | Mirabegron | 130 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 123 | 39 |
| Sertraline Hcl | Sertraline Hcl | 118 | 32 |
| Metformin Hcl Er | Metformin Hcl | 115 | 35 |
| Allopurinol | Allopurinol | 106 | 36 |
| Meloxicam | Meloxicam | 104 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 35 |
| Furosemide | Furosemide | 91 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 30 |
| Alendronate Sodium | Alendronate Sodium | 87 | 24 |
| Donepezil Hcl | Donepezil Hcl | 81 | 24 |
| Simvastatin | Simvastatin | 77 | 25 |
| Celecoxib | Celecoxib | 76 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 75 | 25 |
| Potassium Chloride | Potassium Chloride | 74 | 27 |
| Eliquis | Apixaban | 73 | 29 |
| Buspirone Hcl | Buspirone Hcl | 72 | 27 |
| Jardiance | Empagliflozin | 72 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 20 |
| Mirtazapine | Mirtazapine | 63 | 23 |
| Metformin Hcl | Metformin Hcl | 62 | 23 |
| Alprazolam | Alprazolam | 60 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 21 |
| Ozempic | Semaglutide | 57 | 17 |
| Tramadol Hcl | Tramadol Hcl | 53 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 19 |
| Farxiga | Dapagliflozin Propanediol | 51 | 21 |
| Xarelto | Rivaroxaban | 50 | 17 |
| Carvedilol | Carvedilol | 48 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 13 |
| Lovastatin | Lovastatin | 46 | 14 |
| Montelukast Sodium | Montelukast Sodium | 46 | 17 |
| Spironolactone | Spironolactone | 46 | 14 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Finasteride | Finasteride | 39 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 13 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 28 |
| Valsartan | Valsartan | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Nystatin | Nystatin | 28 | 15 |
| Temazepam | Temazepam | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 20 |
| Cephalexin | Cephalexin | 26 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | 11 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 15 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 15 |
| Prednisone | Prednisone | 24 | 16 |
| Famotidine | Famotidine | 23 | 11 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Clotrimazole | Clotrimazole | 21 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $486.00 · 18 records | Lundbeck LLC | CAPLYTA, Cologuard Collection Kit, FARXIGA, LUISA, REXULTI, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error